Literature DB >> 28477420

The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.

Eveline Boudin1, Timur Yorgan2, Igor Fijalkowski1, Stephan Sonntag3, Ellen Steenackers1, Gretl Hendrickx1, Silke Peeters1, Annelies De Maré4, Benjamin Vervaet4, Anja Verhulst4, Geert Mortier1, Patrick D'Haese4, Thorsten Schinke2, Wim Van Hul1.   

Abstract

Sclerosteosis is a rare autosomal recessive bone disorder marked by hyperostosis of the skull and tubular bones. Initially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin. More recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three sclerosteosis patients. Upon binding to sclerostin, LRP4 can inhibit the canonical WNT signaling that is known to be an important pathway in the regulation of bone formation. To further investigate the role of LRP4 in the bone formation process, we generated an Lrp4 mutated sclerosteosis mouse model by introducing the p.Arg1170Gln mutation in the mouse genome. Extensive analysis of the bone phenotype of the Lrp4R1170Q/R1170Q knock-in (KI) mouse showed the presence of increased trabecular and cortical bone mass as a consequence of increased bone formation by the osteoblasts. In addition, three-point bending analysis also showed that the increased bone mass results in increased bone strength. In contrast to the human sclerosteosis phenotype, we could not observe syndactyly in the forelimbs or hindlimbs of the Lrp4 KI animals. Finally, we could not detect any significant changes in the bone formation and resorption markers in the serum of the mutant mice. However, the serum sclerostin levels were strongly increased and the level of sclerostin in the tibia was decreased in Lrp4R1170Q/R1170Q mice, confirming the role of LRP4 as an anchor for sclerostin in bone. In conclusion, the Lrp4R1170Q/R1170Q mouse is a good model for the human sclerosteosis phenotype caused by mutations in LRP4 and can be used in the future for further investigation of the mechanism whereby LRP4 regulates bone formation.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ANALYSIS/QUANTITATION OF BONE; BONE HISTOMORPHOMETRY; BONE QCT/µCT; CELL/TISSUE SIGNALING; DISEASES AND DISORDERS OF/RELATED TO BONE; GENETIC ANIMAL MODELS; PARACRINE PATHWAYS; WNT/BETA-CATENIN/LRPS

Mesh:

Substances:

Year:  2017        PMID: 28477420     DOI: 10.1002/jbmr.3160

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

Review 1.  Human Genetics of Sclerosing Bone Disorders.

Authors:  Raphaël De Ridder; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

2.  Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.

Authors:  Phillip C Witcher; Sara E Miner; Daniel J Horan; Whitney A Bullock; Kyung-Eun Lim; Kyung Shin Kang; Alison L Adaniya; Ryan D Ross; Gabriela G Loots; Alexander G Robling
Journal:  JCI Insight       Date:  2018-06-07

3.  Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.

Authors:  Svetlana Katchkovsky; Biplab Chatterjee; Chen-Viki Abramovitch-Dahan; Niv Papo; Noam Levaot
Journal:  Cell Mol Life Sci       Date:  2022-01-31       Impact factor: 9.261

4.  Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.

Authors:  Carolina Medina-Gomez; John P Kemp; Katerina Trajanoska; Jian'an Luan; Alessandra Chesi; Tarunveer S Ahluwalia; Dennis O Mook-Kanamori; Annelies Ham; Fernando P Hartwig; Daniel S Evans; Raimo Joro; Ivana Nedeljkovic; Hou-Feng Zheng; Kun Zhu; Mustafa Atalay; Ching-Ti Liu; Maria Nethander; Linda Broer; Gudmar Porleifsson; Benjamin H Mullin; Samuel K Handelman; Mike A Nalls; Leon E Jessen; Denise H M Heppe; J Brent Richards; Carol Wang; Bo Chawes; Katharina E Schraut; Najaf Amin; Nick Wareham; David Karasik; Nathalie Van der Velde; M Arfan Ikram; Babette S Zemel; Yanhua Zhou; Christian J Carlsson; Yongmei Liu; Fiona E McGuigan; Cindy G Boer; Klaus Bønnelykke; Stuart H Ralston; John A Robbins; John P Walsh; M Carola Zillikens; Claudia Langenberg; Ruifang Li-Gao; Frances M K Williams; Tamara B Harris; Kristina Akesson; Rebecca D Jackson; Gunnar Sigurdsson; Martin den Heijer; Bram C J van der Eerden; Jeroen van de Peppel; Timothy D Spector; Craig Pennell; Bernardo L Horta; Janine F Felix; Jing Hua Zhao; Scott G Wilson; Renée de Mutsert; Hans Bisgaard; Unnur Styrkársdóttir; Vincent W Jaddoe; Eric Orwoll; Timo A Lakka; Robert Scott; Struan F A Grant; Mattias Lorentzon; Cornelia M van Duijn; James F Wilson; Kari Stefansson; Bruce M Psaty; Douglas P Kiel; Claes Ohlsson; Evangelia Ntzani; Andre J van Wijnen; Vincenzo Forgetta; Mohsen Ghanbari; John G Logan; Graham R Williams; J H Duncan Bassett; Peter I Croucher; Evangelos Evangelou; Andre G Uitterlinden; Cheryl L Ackert-Bicknell; Jonathan H Tobias; David M Evans; Fernando Rivadeneira
Journal:  Am J Hum Genet       Date:  2018-01-04       Impact factor: 11.025

5.  Maxillary Bone Regeneration Based on Nanoreservoirs Functionalized ε-Polycaprolactone Biomembranes in a Mouse Model of Jaw Bone Lesion.

Authors:  Marion Strub; Xavier Van Bellinghen; Florence Fioretti; Fabien Bornert; Nadia Benkirane-Jessel; Ysia Idoux-Gillet; Sabine Kuchler-Bopp; François Clauss
Journal:  Biomed Res Int       Date:  2018-02-26       Impact factor: 3.411

6.  TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone.

Authors:  Hiroaki Saito; Andreas Gasser; Simona Bolamperti; Miki Maeda; Levi Matthies; Katharina Jähn; Courtney L Long; Hartmut Schlüter; Marcel Kwiatkowski; Vaibhav Saini; Paola Divieti Pajevic; Teresita Bellido; Andre J van Wijnen; Khalid S Mohammad; Theresa A Guise; Hanna Taipaleenmäki; Eric Hesse
Journal:  Nat Commun       Date:  2019-03-22       Impact factor: 14.919

7.  Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis.

Authors:  Annelies De Maré; Stuart Maudsley; Abdelkrim Azmi; Jhana O Hendrickx; Britt Opdebeeck; Ellen Neven; Patrick C D'Haese; Anja Verhulst
Journal:  Toxins (Basel)       Date:  2019-07-21       Impact factor: 4.546

Review 8.  The Role of Sclerostin in Bone and Ectopic Calcification.

Authors:  Annelies De Maré; Patrick C D'Haese; Anja Verhulst
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

9.  Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo.

Authors:  Whitney A Bullock; April M Hoggatt; Daniel J Horan; Andrew J Elmendorf; Amy Y Sato; Teresita Bellido; Gabriela G Loots; Fredrick M Pavalko; Alexander G Robling
Journal:  iScience       Date:  2019-09-18

10.  Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third β-Propeller Domain Can Cause Sclerosteosis.

Authors:  Yentl Huybrechts; Eveline Boudin; Gretl Hendrickx; Ellen Steenackers; Neveen Hamdy; Geert Mortier; Guillermo Martínez Díaz-Guerra; Milagros Sierra Bracamonte; Natasha M Appelman-Dijkstra; Wim Van Hul
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.